Chin Filler Before and After: What the Trials Measured

The searches ask what 1 ml looks like versus 2 ml, and the honest answer is that no chin-filler trial in our research published a before-and-after per milliliter.

What the labels publish are ceilings, and the Restylane Defyne label draws its line precisely: the maximum recommended injected volume per patient per chin treatment is 4 mL — 2 mL in the chin itself plus 2 mL below the lower lip, toward the pre-jowl sulcus.

The Restylane Lyft label caps the chin at the same 4 mL per treatment including touch-up, with no more than 2 mL at any single injection site, and in Lyft's chin trial the injected volume could not exceed 4.0 mL for initial and touch-up treatments combined.

We could not confirm a typical starting amount for the chin from any label or trial in our research, so a 1 ml before-and-after and a 2 ml one are not figures we can put on this page.

The amount of filler a chin gets comes out of a licensed provider's in-person assessment, and the label ceilings are safety limits, not targets.

The approved outcome is written around the profile.

FDA approved Juvéderm Voluma XC for chin augmentation to improve the chin profile on June 12, 2020, Restylane Defyne on January 29, 2021, and Restylane Lyft with Lidocaine on November 4, 2025 — the latter two for augmentation of the chin region to improve the chin profile in mild to moderate chin retrusion, all in patients over 21.

Every other filler injected into chins — including Restylane Refyne, the RHA collection, Radiesse and Juvéderm Volux — holds no chin indication as of October 2026, so chin use of those products is off-label: the use is on no current US label for them.

Chin retrusion is the label term for a chin that sits back from the surrounding profile, and the Defyne and Lyft approvals describe the gel going in under the skin and/or on top of the chin bone — "subcutaneous and/or supraperiosteal", in the regulatory language.

What the trials measured afterward is a graded change.

In Defyne's chin trial, 86.1% of treated subjects had at least a 1-point improvement in chin profile at week 12, versus 6.5% of untreated controls, and the difference over no treatment stayed statistically significant through week 48.

Lyft's chin trial, which tested Lyft against a comparator chin filler, used blinded evaluators — clinicians who did not know which treatment a subject received.

They graded at least a 1-grade chin improvement in 83.6% of subjects at month 3, 75.5% at month 6, 69.1% at month 9 and 69.7% at month 12.

A trial percentage describes the group studied at a study visit, not what any one person will see, and a practice's before-and-after photos document somebody else's result — never a preview of yours.

What the trials cannot tell you — cost, duration, who can legally inject — lives in our chin filler guide, and the chin's neighbor area has its own jawline filler guide.

Straight answer first: none of the chin-filler trials in our research report before-and-after results separately for round faces, so we cannot show you what a round face looked like after treatment, and no percentage above transfers to a face shape the trials never split out.

What the approvals describe is position, not shape: Restylane Defyne and Restylane Lyft are approved for chin augmentation in mild to moderate chin retrusion — a chin that sits back — and placing a chin on that mild-to-moderate scale is part of a licensed provider's in-person exam.

The labels also record who was never studied.

Allergan's ISI states that Voluma XC safety was not studied in patients under 22 or over 80 for chin augmentation, and that Voluma XC was not studied in people with significant loose skin of the chin, neck or jaw — no safety data there, which is not the same as proof a treatment is unsafe.

Roundness and projection are also different dimensions: fullness under the chin is its own concern with its own double chin guide, and how a chin balances the rest of a face is an in-person judgment, not something a trial percentage settles.

The chin approvals name an age, not a sex: all three products are approved in patients over 21, and the trial figures in our research are not split into male and female before-and-afters.

The same limit applies to the female version of this search.

So the honest before-and-after for men — and for women — is the group data in the sections above.

No male-specific or female-specific chin-filler figures turned up in our research, and a consultation is where goals for your own face get discussed and measured.